Table 4.
Univariate analysis
| Favorable prognosis group (n=84) | Unfavorable prognosis group (n=30) | χ2/t | P | |
|---|---|---|---|---|
| Age (years) | 51.4±6.9 | 55.4±7.7 | 2.643 | 0.009 |
| Gender | 0.109 | 0.741 | ||
| Male | 56 (66.67) | 19 (63.33) | ||
| Female | 28 (33.33) | 11 (36.37) | ||
| Duration of dialysis (months) | 30.0±10.7 | 37.4±10.8 | 3.244 | 0.002 |
| Serum creatinine (μmol/L) | 631.96±72.56 | 638.59±54.07 | 0.457 | 0.649 |
| Urea nitrogen (mmol/L) | 17.84±4.83 | 17.38±3.89 | 0.470 | 0.640 |
| Hemoglobin (g/L) | 92.76±8.29 | 90.00±6.82 | 1.635 | 0.105 |
| Albumin (g/L) | 34.79±3.92 | 32.18±4.30 | 3.051 | 0.003 |
| Serum calcium (mmol/L) | 2.44±0.50 | 2.51±0.44 | 0.678 | 0.499 |
| Serum phosphorus (mmol/L) | 1.84±0.43 | 2.06±0.30 | 2.583 | 0.011 |
| Skin pruritus | 6.584 | 0.010 | ||
| Yes | 48 (57.14) | 25 (83.33) | ||
| No | 36 (42.86) | 5 (16.67) | ||
| Primary | 1.856 | 0.603 | ||
| Chronic nephritis | 38 (45.24) | 15 (50.00) | ||
| Hypertensive nephropathy | 13 (15.48) | 5 (16.67) | ||
| Diabetic nephropathy | 19 (22.62) | 8 (26.67) | ||
| Others | 14 (16.67) | 2 (6.67) | ||
| Treatment mode | 2.606 | 0.107 | ||
| Wuling capsule | 48 (57.14) | 12 (40.00) | ||
| Estazolam | 36 (42.86) | 18 (60.00) |